EW vs BSX Stock Comparison: AI Score, Valuation, Performance and Upside
Edwards Lifesciences and Boston Scientific are both major medical device companies with strong positions in cardiovascular care, but Edwards Lifesciences maintains a focused structural heart franchise centered on transcatheter aortic valve replacement, while Boston Scientific offers a more diversified portfolio spanning electrophysiology, endoscopy, and urology alongside its cardiology business.
Edwards Lifesciences offers concentrated exposure to structural heart therapy leadership, while Boston Scientific offers diversified exposure across multiple medical device categories including a fast-growing electrophysiology franchise. Consider whether you prefer Edwards' focused structural heart bet or Boston Scientific's broader diversification.
EW holds the edge across 3 of 5 key metrics in this comparison. EW has delivered stronger 1-year price return (+10.69% vs -55.55%), though BSX has the better forward P/E setup (13.64x vs 26.71x for EW). EW leads on both revenue growth (13.60%) and operating margin (29.84%), suggesting a stronger fundamental setup on both dimensions. Analyst consensus implies meaningfully more upside for BSX (+33.84%) than for EW (+11.92%).
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
- Want concentrated exposure to structural heart disease therapy leadership
- Believe transcatheter aortic valve replacement adoption has continued room to grow globally
- Value deep clinical expertise focused on a specific therapeutic area
- Are comfortable with revenue concentration risk in a single medical device category
- Prefer diversified exposure across cardiology, electrophysiology, endoscopy, and urology
- Believe the growing electrophysiology franchise offers a meaningful long-term growth driver
- Value broad commercial infrastructure supporting multiple device categories
- Want reduced reliance on any single product line for overall company growth
| Metric | EW | BSX |
|---|---|---|
| AI scorei | 41.4 | 39.1 |
| AI ranki | #922 | #1149 |
| Latest closei | $89.90 | $47.80 |
| 1M returni | +1.05% | +0.13% |
| 6M returni | +7.16% | -34.51% |
| 1Y returni | +10.69% | -55.55% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | EW | BSX |
|---|---|---|
| 1Y ago | $11.1K (+11.0%) started 2025-09-04 | $4.46K (-55.4%) started 2025-09-04 |
| 5Y ago | $7.37K (-26.3%) started 2021-09-07 | $10.6K (+6.0%) started 2021-09-07 |
| 10Y ago | $22.95K (+129.5%) started 2016-09-06 | $19.65K (+96.5%) started 2016-09-06 |
Hypothetical — past performance does not guarantee future results.
| Metric | EW | BSX |
|---|---|---|
| Market capi | $52B | $67.88B |
| Trailing P/Ei | 53.70 | 18.96 |
| Forward P/Ei | 26.71 | 13.64 |
| Price/Salesi | N/A | N/A |
| EV/Revenuei | 7.46 | 3.82 |
| Analyst targeti | $100.96 | $62.69 |
| Target upsidei | +11.92% | +33.84% |
| Metric | EW | BSX |
|---|---|---|
| Revenue growthi | 13.60% | 7.50% |
| Earnings growthi | -25.40% | 15.10% |
| EPS growthi | -25.40% | +15.10% |
| FCF margini | +18.92% | +11.68% |
| Operating margini | 29.84% | 22.90% |
| Profit margini | 15.43% | 17.50% |
| ROIC proxyi | 9.18% | 15.34% |
| Return on equityi | 9.18% | 15.34% |
| Dividend yieldi | N/A | N/A |
| Betai | 0.85 | 0.57 |
| Debt/equityi | 6.57 | 50.15 |
| Current ratioi | 4.52 | 1.24 |
| Quick ratioi | 3.45 | 0.56 |
Over the past year, EW and BSX have moved weakly in the same direction (correlation of 0.29), based on daily returns.
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | EW | BSX |
|---|---|---|---|
| 1Y | Growthi | +11.04% | -55.45% |
| CAGRi | +11.06% | -55.50% | |
| Volatilityi | 24.49% | 37.28% | |
| Sharpe ratioi | 0.37 | -2.09 | |
| Sortino ratioi | 0.55 | -2.45 | |
| Max drawdowni | 13.19% | 60.58% | |
| Current drawdowni | 5.55% | 55.80% | |
| Avg drawdowni | 4.58% | 31.81% | |
| Ulcer Indexi | 5.65% | 37.76% | |
| Max daily dropi | 3.64% | 17.59% | |
| Max wkly dropi | 7.40% | 19.50% | |
| 5Y | Growthi | -26.31% | +5.99% |
| CAGRi | -5.93% | +1.17% | |
| Volatilityi | 32.71% | 26.35% | |
| Sharpe ratioi | -0.15 | 0.01 | |
| Sortino ratioi | -0.19 | 0.01 | |
| Max drawdowni | 54.32% | 60.58% | |
| Current drawdowni | 31.21% | 55.80% | |
| Avg drawdowni | 34.33% | 10.12% | |
| Ulcer Indexi | 36.37% | 18.07% | |
| Max daily dropi | 31.34% | 17.59% | |
| Max wkly dropi | 30.43% | 19.50% | |
| 10Y | Growthi | +129.45% | +96.47% |
| CAGRi | +8.67% | +6.99% | |
| Volatilityi | 32.23% | 27.63% | |
| Sharpe ratioi | 0.29 | 0.22 | |
| Sortino ratioi | 0.39 | 0.30 | |
| Max drawdowni | 54.32% | 60.58% | |
| Current drawdowni | 31.21% | 55.80% | |
| Avg drawdowni | 20.99% | 9.19% | |
| Ulcer Indexi | 26.79% | 15.06% | |
| Max daily dropi | 31.34% | 17.59% | |
| Max wkly dropi | 30.43% | 19.55% |
| Category | EW | BSX |
|---|---|---|
| Company | Edwards Lifesciences Corporation | Boston Scientific Corporation |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Medical Devices |
| Core business | A medical technology company focused on structural heart disease and critical care monitoring, best known for pioneering transcatheter aortic valve replacement therapy used to treat heart valve disease without open-heart surgery. | A diversified medical device company with a broad portfolio spanning cardiology, electrophysiology, endoscopy, and urology, including a growing electrophysiology franchise focused on treating irregular heart rhythms. |
| Investor focus | Transcatheter aortic valve replacement adoption growth and international expansion, structural heart pipeline progress, and competitive dynamics within the heart valve therapy market. | Electrophysiology franchise revenue growth, structural heart product pipeline progress, and overall diversification benefits across its multiple medical device business segments. |
- Pioneering position in transcatheter aortic valve replacement therapy established early leadership in a large, growing treatment category
- Focused structural heart portfolio allows deep clinical expertise and sustained research investment in a specific therapeutic area
- Critical care monitoring business provides diversification alongside its core structural heart franchise
- Diversified medical device portfolio across cardiology, electrophysiology, endoscopy, and urology reduces reliance on any single product category
- Growing electrophysiology franchise addresses a large and expanding market for irregular heart rhythm treatment
- Broad commercial infrastructure and physician relationships support the launch and adoption of new devices across categories
- Faces increasing competition in transcatheter aortic valve replacement from other large medical device manufacturers
- Revenue concentration in structural heart therapies creates exposure to procedure volume and reimbursement changes
- New pipeline therapies must continue to gain regulatory approval and clinical adoption to sustain growth
- Operates in numerous competitive medical device categories, requiring sustained investment to maintain share across each
- Growth in newer categories like electrophysiology must continue to offset any maturity in legacy device lines
- Faces the typical regulatory and product recall risks inherent in operating a broad medical device portfolio
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.